血液灌流:技术层面与最新进展
本文为叙述性综述,评估体外、动物及人体研究,聚焦血液灌流的技术、特征与原理。早期研究受生物不相容性限制,近期涂层与生产技术提高了吸附剂生物相容性与安全性。血液灌流在慢性透析和慢性肝病中显示正面效果,在药物过量时可提取多种毒物和药物。内毒素结合多黏菌素B在脓毒症休克中结果不一,正在积极研究中;非选择性血液灌流在脓毒症或炎症中的作用仍未确定。
要点
- 早期血液灌流研究受生物不相容性困扰,近期生产与涂层技术提高了吸附剂生物相容性和安全性。
- 血液灌流在慢性透析和慢性肝病中已显示正面效果。
- 在药物过量时,血液灌流已证明可提取多种毒物和药物。
- 内毒素结合多黏菌素B在脓毒症休克中结果不一,正在积极研究中。
- 非选择性血液灌流在脓毒症或炎症中的作用仍未确定,该领域研究议程仍然庞大。
适用人群与场景
- 慢性透析患者
- 慢性肝病患者
- 药物过量中毒患者
- 脓毒症休克患者(内毒素结合多黏菌素B研究场景)
研究设计与关键结果
- 本文为叙述性综述,评估体外、动物及人体研究,聚焦血液灌流技术、特征与原理。
- 早期血液灌流研究受生物不相容性阻碍;近期技术提高了安全性。
- 血液灌流在慢性透析和慢性肝病中已显示正面效果。
- 血液灌流在药物过量时已证明可提取多种毒物和药物。
- 内毒素结合多黏菌素B在脓毒症休克中结果不一,正在积极研究中。
- 非选择性血液灌流在脓毒症或炎症中的作用仍未确定。
证据类型、等级与局限
- 证据类型:叙述性综述,纳入体外、动物及人体研究。
- 原文指出早期研究受生物不相容性限制,近期技术改善安全性。
- 原文指出内毒素结合多黏菌素B在脓毒症休克中结果不一,正在积极研究。
- 原文指出非选择性血液灌流在脓毒症或炎症中的作用仍未确定。
- 原文指出新吸附剂血液灌流的系统研究既有必要也合理。
对床旁实践的改变
- 作者认为,新型吸附剂因生物相容性和安全性更高而明显不同于过去使用的吸附剂。
- 作者认为,新型吸附剂血液灌流的初步研究在特定慢性病和部分急性状态中显示出一定前景。
- 作者认为,新型吸附剂血液灌流的系统研究现在既有必要也合理。
指南或共识出处
- 本文为发表于Crit Care的叙述性综述,无具体指南或共识名称。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Blood purification through the removal of plasma solutes by adsorption to beads of charcoal or resins contained in a cartridge (hemoperfusion) has a long and imperfect history. Developments in production and coating technology, however, have recently increased the biocompatibility of sorbents and have spurred renewed interest in hemoperfusion.
METHODS: We performed a narrative assessment of the literature with focus on the technology, characteristics, and principles of hemoperfusion. We assessed publications in ex vivo, animal, and human studies. We synthesized such literature in a technical and state-of-the-art summary.
RESULTS: Early hemoperfusion studies were hampered by bioincompatibility. Recent technology, however, has improved its safety. Hemoperfusion has been used with positive effects in chronic dialysis and chronic liver disease. It has also demonstrated extraction of a variety of toxins and drugs during episodes of overdose. Trials with endotoxin binding polymyxin B have shown mixed results in septic shock and are under active investigation. The role of non-selective hemoperfusion in sepsis or inflammation remains. Although new technologies have made sorbents more biocompatible, the research agenda in the field remains vast.
CONCLUSION: New sorbents markedly differ from those used in the past because of greater biocompatibility and safety. Initial studies of novel sorbent-based hemoperfusion show some promise in specific chronic conditions and some acute states. Systematic studies of novel sorbent-based hemoperfusion are now both necessary and justified.
参考来源
- Ronco C, Bellomo R. Hemoperfusion: technical aspects and state of the art. Crit Care. 2022. PMID: 35549999. doi:10.1186/s13054-022-04009-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。